S&P 500
5,911.69
-0.0%
-$0.48
DJI
42,270.07
+0.1%
+$54.34
NASDAQ
19,113.77
-0.3%
-$62.11
Bitcoin
104,011.00
-1.3%
-1,354.85
AAPL
$201.47
+0.8%
+$1.52
AMZN
$205.07
-0.3%
-$0.63
GOOG
$173.06
+0.1%
+$0.10
META
$648.23
+0.5%
+$3.18
MSFT
$460.71
+0.4%
+$2.03
NVDA
$135.22
-2.9%
-$3.97
TSLA
$346.82
-3.2%
-$11.61
Gyre Therapeutics (NASDAQ: GYRE)
$9.10
(-3.8%)
-$0.36
Price as of May 30, 2025, 3:58 p.m. ET
Gyre Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Gyre Therapeutics Company Info
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. It is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis). The company was founded on March 7, 1997 and is headquartered in San Diego, CA.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.